The landscape of preclinical research is undergoing a profound metamorphosis. For decades, the paradigm of drug discovery has been linear and resource-intensive: study designs were crafted, animal models were utilized, and the resulting tissue samples were analyzed, recorded, and eventually relegated to long-term storage as "passive" archives. However, the convergence of high-resolution digital pathology and artificial intelligence (AI) is transforming these dormant archives into goldmines of actionable data.
As the industry pivots toward the "3Rs" (Replacement, Reduction, and Refinement) in animal testing, researchers are discovering that the most effective way to spare future animal studies may lie in the meticulous analysis of those already completed.
The Paradigm Shift: From Physical Slides to Data Assets
Historically, the pathology workflow functioned as a one-way street. A pathologist would examine a glass slide, dictate a report, and the physical specimen would be filed away in a cabinet, rarely to be viewed again. The COVID-19 pandemic served as a catalyst for change; forced to work remotely, pathologists began digitizing slides to ensure business continuity. This transition from physical glass to digital pixels proved to be a watershed moment for the field.
"Before, the pathology endpoint was just a report," explains Dr. Aleksandra Zuraw, a veterinary pathologist at Charles River Laboratories. "Now, you have the digitized slide, which is essentially a massive dataset of pixels."
This shift has enabled researchers to move beyond traditional morphology. By coupling digitized imagery with historical pathology reports and molecular data, AI models can now be trained to recognize subtle biological patterns that were previously invisible to the human eye. The slide is no longer a terminal record; it is a dynamic source of data capable of answering research questions that were not even conceived at the time of the initial study.
Chronology of a Digital Transformation
The path toward this data-centric future has been accelerated by both technological breakthroughs and shifting regulatory landscapes:
- Pre-2020: Digital pathology is a niche interest, primarily used for education or occasional remote consultation.
- 2020–2021: The pandemic mandates widespread adoption of digital workflows, creating a massive repository of digitized slide images.
- 2022: The enactment of the FDA Modernization Act 2.0 signals a landmark shift, allowing for non-animal methods to support human trial applications.
- 2024: Charles River Laboratories launches its Alternative Methods Advancement Project (AMAP), formalizing the shift toward New Approach Methodologies (NAMs).
- 2025: The OECD releases comprehensive guidance on sample collection for omics analysis, establishing standards for the use of preserved tissue in modern molecular investigations.
- 2026: The FDA updates regulations to further advance innovative alternatives, cementing the agency’s commitment to making animal testing the exception rather than the rule within the next three to five years.
Virtual Controls and the Arithmetic of Reduction
One of the most immediate impacts of this digital transition is the implementation of "virtual control groups." In traditional toxicology studies, a significant number of animals must be allocated to control groups to provide a baseline for comparison.
By leveraging vast libraries of historical data—ensuring that study conditions, genetics, and environmental factors are matched—researchers can effectively replace a portion of the physical control animals with data-driven virtual models. As Dr. Zuraw notes, "Control animals are a large fraction of every study. By replacing some of them with matched historical data, we reduce the total number of animals needed through simple, robust arithmetic."
The challenge, of course, lies in the rigor of the matching. Researchers must prove that the historical data is sufficiently comparable to the current study to avoid "noise" being misinterpreted as a drug effect. Charles River’s current efforts are focused on generating enough high-fidelity, matched datasets to make virtual controls a standard, reliable feature across all preclinical trials.
The Hidden Value of FFPE Blocks
While digitized images provide the "what" of a sample, the original Formalin-Fixed, Paraffin-Embedded (FFPE) blocks stored in archives contain the "why." These blocks remain stable for years, preserving molecular information regarding how cells and organs responded to specific chemical compounds.
When an unexpected outcome emerges after a study concludes, researchers previously had few options other than initiating a new, expensive, and time-consuming animal study. Now, they can return to the archived blocks. By utilizing modern molecular testing—such as gene expression and protein analysis—on these legacy samples, scientists can extract new insights without the need for additional living models.
The OECD’s 2025 guidelines emphasize that while sample preparation is crucial for quality, archived tissue is a legitimate and powerful asset. By integrating these molecular findings with original dosing information and digital pathology images, researchers can conduct multi-dimensional analyses that bridge the gap between initial toxicology screenings and advanced biological understanding.
Regulatory Implications: From Exception to Default
The regulatory climate has shifted from passive observation to active encouragement of NAMs. The FDA’s roadmap, published in April 2025, provides a clear, time-bound trajectory: starting with monoclonal antibodies and expanding to chemical entities, the goal is to reduce the reliance on animal testing significantly.
This regulatory pressure is transforming the business of drug discovery. Labs are no longer just service providers; they are becoming data repositories. The ability to demonstrate compliance with these new methods requires "early adopters"—laboratories that troubleshoot the technical hurdles and establish the precedent that others can follow. As Dr. Zuraw highlights, "You need early adopters to figure it out, to troubleshoot, and to set the standard so that the rest of the industry doesn’t have to reinvent the wheel."
Cutting-Edge Frontiers: Virtual Staining
Beyond the mining of existing data, the field is pushing into "virtual staining." This technology allows scanners to capture images of unstained tissue and apply software-based algorithms to generate a visual representation of stains.
This process effectively bypasses the need for chemical staining and, in some experimental contexts, potentially the glass slides themselves. While still in its nascent stages of clinical standardization, the acceleration of virtual staining applications across various tissue types since 2019 suggests a future where digital pathology is entirely decoupled from the physical logistics of the traditional lab.
A Snowball Effect for Drug Discovery
The vision for the future is a "snowball effect." As labs invest in the infrastructure required to digitize and store slides, the value of those archives increases exponentially. This creates a virtuous cycle:
- Increased Data Access: More slides are digitized, creating larger, more diverse datasets.
- Improved AI Models: Larger datasets lead to more accurate AI, which in turn uncovers deeper insights.
- Reduced Animal Reliance: Greater insight leads to fewer necessary experiments, fulfilling regulatory and ethical mandates.
This is not merely about digitizing a process; it is about re-conceptualizing the tissue sample as a permanent, re-usable data point. For the pharmaceutical industry, this shift promises not only significant cost reductions and faster timelines but also a more ethical, precise, and sustainable approach to drug discovery.
As the industry moves forward, the integration of legacy data with cutting-edge analytical tools will define the next generation of preclinical research. The "old" tissue sitting in storage is no longer a relic of the past; it is the key to a more efficient and humane future in medicine.
About the Author
